Initiator Pharma reported reduced losses and strengthened equity in H1 2024, advanced pudafensine with new patent filings, and saw continued progress in its ED and FSD clinical programs. The company remains focused on clinical development and partnering opportunities.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.